Corticotropin gel - Mallinckrodt

Drug Profile

Corticotropin gel - Mallinckrodt

Alternative Names: Acthar®; Acthar® Gel; Adrenocorticotropin gel - Mallinckrodt; H.P. Acthar Gel; Repository corticotropin injection - Mallinckrodt

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer Mallinckrodt plc
  • Class Anterior pituitary hormones; Antiepileptic drugs; Corticosteroids; Hypothalamic hormones
  • Mechanism of Action Corticotropin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Marketed Adrenal cortex disorders; Ankylosing spondylitis; Infantile spasms; Juvenile rheumatoid arthritis; Membranous glomerulonephritis; Multiple sclerosis; Nephrotic syndrome; Polymyositis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus
  • Phase II Amyotrophic lateral sclerosis; Diabetic nephropathies

Most Recent Events

  • 01 Mar 2017 Mallinckrodt plans a phase II trial for Amyotrophic lateral sclerosis (SC, Injection) (NCT03068754)
  • 21 Nov 2016 The US FDA grants the Fast Track designation for Mallinckrodt's IND application for Amyotrophic lateral sclerosis
  • 21 Nov 2016 Mallinckrodt completes a phase II trial in Amyotrophic lateral sclerosis in USA prior to November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top